Revelation Biosciences REVB
NASDAQ REVB
$3.67 -0.08 (-2.13%)
As of: Oct 21, 2026 · 12:51 PM EDT

Revelation Biosciences (REVB) Debt Ratio (2020 - 2021)

Updated

Revelation Biosciences' Debt Ratio came in at 0.38 for Q4 2021.

Analysis

Revelation Biosciences (REVB) Debt Ratio (2020 - 2021) Analysis & Trends

  • The Q4 2021 figure represents the lowest quarterly Debt Ratio since Q3 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Eli Lilly 1,133.08 Bn 1,101.67 Bn 19.71 Bn 0.39
2 Johnson & Johnson 616.40 Bn 534.93 Bn 17.26 Bn 0.24
3 AbbVie 501.19 Bn 474.31 Bn 12.70 Bn 0.52
4 Merck 367.18 Bn 321.56 Bn 12.21 Bn 0.42
5 Novartis Ag 297.99 Bn 261.98 Bn 11.24 Bn 0.08
6 Astrazeneca 261.67 Bn 235.36 Bn 12.86 Bn 0.28
7 Amgen 235.57 Bn 190.97 Bn 7.24 Bn 0.60
8 Gilead Sciences 190.62 Bn 164.82 Bn 6.22 Bn 0.53
9 Pfizer 169.63 Bn 116.28 Bn 10.94 Bn 0.31
10 Revelation Biosciences 14.05 Mn -34.97 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 0.38
Sep 30, 2020 0.04
API Access

Revelation Biosciences Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=REVB&period=max&api_key=YOUR_API_KEY